Trillium Therapeutics Inc.
CD47 BLOCKADE THERAPY WITH CD38 ANTIBODY

Abstract:

CD47+ disease cells such as cancer cells are treated using a combination of CD47 blocking agent and a CD38 antibody such as daratumumab. The anti-cancer effect of SIRP.alpha.Fc is enhanced in the presence of daratumumab. Specific combinations include SIRP.alpha.Fc forms that comprise an Fc that is either IgG1 or IgG4 isotype. These combinations are useful particularly to treat blood cancers including lymphomas, leukemias and myelomas.